New Drug Approvals to Drive Kidney Cancer Drugs Market to USD 5.2 Billion by 2020

New Drug Approvals to Drive Kidney Cancer Drugs Market to USD 5.2 Billion by 2020

Kidney Cancer Drugs Market – Global Drug Types (Brand) and Clinical Pipeline Analysis and Forecast 2016-2020, estimates the global kidney cancer drugs market to reach nearly USD 5.2 Billion in 2020, at a CAGR of 6.5% from 2016 to 2020 – iHealthcareAnalyst, Inc.

Visit the Kidney Cancer Drugs Market – Global Drug Types (Brand) and Clinical Pipeline Analysis and Forecast 2016-2020 report https://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/

Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers. They can often shrink or slow the growth of the cancer for a time, but it doesn’t seem that any of these drugs can actually cure kidney cancer. Several targeted drugs can be used to treat advanced kidney cancer. These drugs block angiogenesis (growth of the new blood vessels that nourish cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive. The global kidney cancer drugs market report estimates the market size (Revenue USD million – 2013 to 2020) for key market segments based on the drug type (brand) such as Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib), clinical phase 1, 2 and 3 drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) pipeline analysis, and forecasts growth trends (CAGR% – 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

The global biomedical waste management services market is segmented as:

  1. Brand Type
    • Afinitor (Everolimus)
    • Avastin (Bevacizumab)
    • Inlyta (Axitinib)
    • Nexavar (Sorafenib)
    • Proleukin (Aldesleukin)
    • Sutent (Sunitinib)
    • Torisel (Temsirolimus)
    • Votrient (Pazopanib)
  1. Clinical Pipeline Analysis (Phase 3 Drugs)
    • AGS-003
    • Cabozantinib (XL184)
    • Dovitinib (TK1258)
    • Keytruda (Anti PD 1) (Pembrolizumab)
    • Opdivo (Nivolumab)
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World
  1. Company Profiles
    • Bayer AG
    • Bristol-Myers Squibb
    • Hoffmann-La Roche, Ltd.
    • GlaxoSmithKline, plc.
    • Merck & Co., Inc.)
    • Novartis AG
    • Pfizer, Inc.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2017-03-21T11:28:24+00:00 Categories: Press Releases|
Translate »